Figure 2 | Scientific Reports

Figure 2

From: Supporting the gastrointestinal microenvironment during high-dose chemotherapy and stem cell transplantation by inhibiting IL-1 signaling with anakinra

Figure 2

Anakinra mitigates melphalan-induced mucosal barrier injury and clinical manifestations of gut toxicity. (A) Mucosal barrier injury defined by plasma citrulline showed a significant decrease in MEL + ANA at D + 2 and D + 4 compared to melphalan only. (B–C) Anakinra prevented melphalan-induced weight loss and food intake (D–E). Data presented as mean ± SEM. N = 8/group, all analyzed longitudinally using a mixed-effects model with Geisser-Greenhouse correction, with the exception of panel (E) which used a one-way ANOVA with Tukey’s post-hoc.

Back to article page